Earnings Reports
Filter News
Found 56,758 articles
-
AveXis, a Novartis company based in Illinois, is investing $55 million to build a new manufacturing facility in Durham, North Carolina.
-
McKesson Reports Fiscal 2018 Fourth-Quarter and Full-Year Results
5/24/2018
Revenues of $51.6 billion for the fourth quarter and $208.4 billion for the full year.
-
CollPlant Reports First Quarter 2018 Financial Results and Provides Business Update
5/24/2018
CollPlant is a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products
-
Webcast Alert: Ionis Pharmaceuticals Provides Corporate Update at 2018 Annual Meeting of Stockholders
5/23/2018
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present a general corporate update in conjunction with its 2018 Annual Meeting of Stockholders and Open House on Wednesday, May 23 at 2:10 p.m. Pacific Time (5:10 p.m. Eastern Time) in Carlsbad, CA.
-
Dr. Reddy’s Q4 and FY18 Financial Results
5/22/2018
Dr. Reddy's Laboratories, Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2018 under International Financial Reporting Standards (IFRS).
-
NeuroVive Pharmaceutical AB Interim Report January - March 2018
5/22/2018
NeuroVive decided to conduct a rights issue for the continued development of the company's drug projects following shareholder approval at an Extraordinary General Meeting.
-
Merck Announces Third-Quarter 2018 Dividend
5/22/2018
Merck(NYSE:MRK), today announced that the Board of Directors has declared a quarterly dividend of $0.48 per share of the company’s common stock.
-
NanoViricides Files Quarterly Report for Period Ending March 31, 2018; Company Has Over A Year's Worth of Cash in Hand, and It Is Scaling Up Production of Certain Herpecide Program Drug Candidates
5/22/2018
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), filed its quarterly report for its third quarter of financial year 2018.
-
PAVmed Reports First Quarter 2018 Financial Results
5/22/2018
Conference call to be held May 30, 2018 at 4:30 p.m. Eastern time
-
BioLineRx Reports First Quarter 2018 Financial Results
5/22/2018
Steady progress made on multiple clinical trials for the Company's lead oncology program, BL-8040
-
Nabriva Therapeutics' New Antibiotic Shows Promise in Phase III Trial of Bacterial Pneumonia
5/21/2018
Nabriva Therapeutics reported positive topline results from its Phase III clinical trial of oral lefamulin compared to oral moxifloxacin in adults with moderate community-acquired bacterial pneumonia (CABP). -
Anpac Bio Revenue Surges Nearly 300% After Signing 15th Global Fortune 500 Company Customer
5/21/2018
Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, confirmed the company's 2018 revenue vaulted nearly 300%.
-
Accent Therapeutics Announces Company Launch with $40 Million Series A Financing for Novel, Precision Cancer Treatments Targeting RNA-Modifying Proteins
5/18/2018
Company establishes platform strategy to lead development of promising new precision therapies in the emerging field of epitranscriptomics
-
Shineco, Inc. Reports Third Quarter of 2018 Financial Results
5/17/2018
Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural produce, specialized textiles, and other health and well-being focused plant-based products in China, announced today its financial results for the third quarter ended March 31, 2018.
-
Cellect Biotechnology Ltd Provides Corporate Update and Reports First Quarter 2018 Financial Results
5/17/2018
Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate update and announced financial results for the first quarter ended March 31, 2018.
-
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results
5/17/2018
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the third quarter ended March 31, 2018. DelMar executive management will host a business update conference call for investors, analysts and other interested parties on May 30, 2018 at 4:30 p.m. Eastern Time.
-
Medicure Q1 2018 Results and Conference Call Dates
5/17/2018
Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the first quarter ended March 31, 2018 on Wednesday, May 23, 2018.
-
Taro Provides Results for Year Ended March 31, 2018
5/17/2018
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2018.
-
Griffin-American Healthcare REIT III Reports First Quarter 2018 Results
5/17/2018
Griffin-American Healthcare REIT III, Inc. today announced operating results for the company's first quarter ended March 31, 2018.
-
BioLineRx to Report First Quarter 2018 Results on May 22, 2018
5/16/2018
Management to hold a conference call at 10:00 a.m. EDT